ライフサイエンスコーパス: decompensated cirrhosis

1 e systemic immune responses in patients with decompensated cirrhosis.

2 te exacerbation of the SI already present in decompensated cirrhosis.

3 ot been extensively studied in patients with decompensated cirrhosis.

4 should be used with caution in patients with decompensated cirrhosis.

5 response in patients with HCV infection and decompensated cirrhosis.

6 on, including transplantation for those with decompensated cirrhosis.

7 rgery with excellent outcomes for those with decompensated cirrhosis.

8 ould be considered in patients admitted with decompensated cirrhosis.

9 patients with genotypes 2 or 3 infection and decompensated cirrhosis.

10 annual number of IDUs developing HCV-related decompensated cirrhosis.

11 g mortality in patients with compensated and decompensated cirrhosis.

12 nt of patients admitted to the hospital with decompensated cirrhosis.

13 in the prevalence of cirrhosis (1.7%-2.2%), decompensated cirrhosis (1.1%-1.2%), and HCC (0.03%-0.13

14 in the prevalence of cirrhosis (3.5%-13.2%), decompensated cirrhosis (1.9%-5.8%), and HCC (0.07%-1.6%

15 produced the largest absolute reductions in decompensated cirrhosis (16%) and hepatocellular carcino

16 is hypothesis and included 522 patients with decompensated cirrhosis (237 with ACLF) and 40 healthy s

17 32% had a diagnosis of cirrhosis (9.9% with decompensated cirrhosis), 36% had a Fibrosis-4 index sco

18 ort screening leads to 84,000 fewer cases of decompensated cirrhosis, 46,000 fewer cases of hepatocel

19 Among the full cohort with compensated or decompensated cirrhosis, 61% (504 of 830) died during th

20 f patients with HIV who had cirrhosis (66%), decompensated cirrhosis (62%), and HCC (80%).

21 could prevent approximately 124,200 cases of decompensated cirrhosis, 78,800 cases of hepatocellular

22 cs of systemic inflammation in patients with decompensated cirrhosis and ACLF, with special emphasis

23 Characteristics of decompensated cirrhosis and acute-on-chronic liver failu

24 Primary HCV infection resulted in decompensated cirrhosis and death within 2-8 years in 4

25 the only effective therapy for patients with decompensated cirrhosis and fulminant liver failure.

26 V, the number of individuals with cirrhosis, decompensated cirrhosis and HCC will continue to increas

27 f patients developing HCV-related cirrhosis, decompensated cirrhosis and HCC will increase substantia

28 s of end-stage liver disease (ESLD), such as decompensated cirrhosis and liver cancer.

29 long the survival of rats with irreversible, decompensated cirrhosis and may be useful in the treatme

30 st cost-effective strategy for patients with decompensated cirrhosis and MELD score greater than 13.

31 Recommendations for management of decompensated cirrhosis and of recurrent hepatitis C aft

32 17 HBsAg-positive patients with decompensated cirrhosis and previous evidence of viral r

33 c function in over half of the patients with decompensated cirrhosis and replicating HBV, and may con

34 re now presenting in increasing numbers with decompensated cirrhosis and the need for liver transplan

35 controlled trials of adults (>18 years) with decompensated cirrhosis and type 1 hepatorenal syndrome

36 ons of portal hypertension is a harbinger of decompensated cirrhosis and warrants consideration for l

37 ver function in patients with compensated or decompensated cirrhosis, and delay or obviate the need f

38 lculated the annual prevalence of cirrhosis, decompensated cirrhosis, and HCC in a national sample of

39 time trends in the prevalence of cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma (H

40 ency is common among patients with HCV, with decompensated cirrhosis, and in the posttransplant setti

41 treatment of CHB in pregnancy, coinfection, decompensated cirrhosis, and posttransplant is safe and

42 interferon-alpha, the cost of treatment for decompensated cirrhosis, and quality of life in patients

43 patient with hemochromatosis, alcohol abuse, decompensated cirrhosis, and spur cell anemia who had a

44 nd decreased renal blood flow, patients with decompensated cirrhosis are very susceptible to developi

45 ents with cirrhosis, particularly those with decompensated cirrhosis, are at increased risk of bacter

46 18 years or older with any HCV genotype and decompensated cirrhosis at screening.

47 advanced liver disease, including those with decompensated cirrhosis before and after liver transplan

48 advanced liver disease, including those with decompensated cirrhosis before or after liver transplant

49 bservational cohort study of inpatients with decompensated cirrhosis between 2010 and 2013.

50 erial infections are common complications in decompensated cirrhosis, but their relationship with hem

51 tes incubated with plasma from patients with decompensated cirrhosis carrying the protective SNP geno

52 ficial effect of lamivudine in patients with decompensated cirrhosis caused by replicating hepatitis

53 ected with HCV genotypes 1 through 6 who had decompensated cirrhosis (classified as Child-Pugh-Turcot

54 therapy, recently approved for patients with decompensated cirrhosis (DC) secondary to hepatitis C vi

55 hronic HCV only, 9% with cirrhosis, 12% with decompensated cirrhosis (DCC), 2% with liver cancer, 2%

56 ients with hepatocellular carcinoma (HCC) or decompensated cirrhosis (DCC).

57 re grouped into HBV-related (subdivided into decompensated cirrhosis [DCC] and hepatocellular carcino

58 Six patients have died; 1 patient with decompensated cirrhosis died of variceal bleeding.

59 The prevalence of patients with decompensated cirrhosis doubled, from 5% in 1996 to 11%

60 rcaserin in a morbidly obese individual with decompensated cirrhosis evaluated for LT listing.

61 ecrease the 15-year cumulative incidences of decompensated cirrhosis from 12.2% to 4.5%, hepatocellul

62 ificantly larger proportion of patients with decompensated cirrhosis given a combination of G-CSF and

63 nt-reported outcomes (PROs) in patients with decompensated cirrhosis given a fixed-dose combination o

64 Patients with decompensated cirrhosis have significantly reduced survi

65 f HCV incidence, prevalence, compensated and decompensated cirrhosis, hepatocellular carcinoma, liver

66 H-fibrosis, NASH-compensated cirrhosis, NASH-decompensated cirrhosis, hepatocellular carcinoma, liver

67 esponse, chronic HCV, compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, liver

68 ge IV disease (HR, 1.40; 95% CI, 1.24-1.58), decompensated cirrhosis (HR, 1.49; 95% CI, 1.30-1.70), a

69 The number of IDUs developing HCV-related decompensated cirrhosis in Scotland is estimated to doub

70 cellular carcinoma, and 203,000 will develop decompensated cirrhosis in the next 35 years.

71 Management of obesity and decompensated cirrhosis in those requiring liver transpl

72 advanced liver disease, including those with decompensated cirrhosis, in routine practice (all curren

73 , for patients admitted to the hospital with decompensated cirrhosis, individuals who were managed by

74 Decompensated cirrhosis is characterized by disturbed sy

75 irus (HCV) ages, the number of patients with decompensated cirrhosis is expected to increase.

76 including patients with HIV/HCV coinfection, decompensated cirrhosis, liver and kidney transplants, a

77 ging from early, ambulatory-phase disease to decompensated cirrhosis necessitating liver transplantat

78 were studied in patients with hypotension or decompensated cirrhosis of the liver.

79 e risk of infection in patients with acutely decompensated cirrhosis or ESLD.

80 ical treatments that can halt progression to decompensated cirrhosis or even reverse cirrhosis are cu

81 ction of any genotype and either compensated/decompensated cirrhosis or posttransplantation recurrenc

82 al need is great, treatment of patients with decompensated cirrhosis or with recurrent hepatitis C af

83 eatening liver disease (acute liver failure, decompensated cirrhosis, or severe hepatitis flare) and

84 nsideration are patients with compensated or decompensated cirrhosis, organ transplantation, acute he

85 utive patients admitted to the hospital with decompensated cirrhosis over a 1-year period were identi

86 underwent liver transplantation at UCLA for decompensated cirrhosis owing to a jejunoileal bypass we

87 that the optimal MELD threshold below which decompensated cirrhosis patients should receive HCV trea

88 One patient who had decompensated cirrhosis prior to treatment initiation di

89 Patients with decompensated cirrhosis receiving DAAs present lower res

90 Three patients are described who developed decompensated cirrhosis requiring retransplantation desp

91 CI], 2.62-4.49; P < .001, log-rank test) and decompensated cirrhosis (RR = 4.11; 95% CI, 2.95-5.70; P

92 [CI]=1.11-2.11; log-rank test; P<0.001) and decompensated cirrhosis (RR=2.01; 95% CI=1.07-3.79; log-

93 prospective study, consecutive patients with decompensated cirrhosis seen at the Institute of Liver a

94 0.61; 95% CI, 0.47-0.79) among patients with decompensated cirrhosis, the median survival benefit was

95 ended in specific patient groups: those with decompensated cirrhosis, those coinfected with human imm

96 e probability of survival after diagnosis of decompensated cirrhosis was 81.8 and 50.8% at 1 and 5 ye

97 267 patients with HCV-related decompensated cirrhosis were included.

98 ASTRAL-4) in which patients with HCV-related decompensated cirrhosis were randomly assigned to an all

99 th fibrosing cholestatic hepatitis (FCH) and decompensated cirrhosis who had a life expectancy of 1 y

100 Os was observed in patients with HCV-related decompensated cirrhosis who were given sofosbuvir and ve

101 ve was to identify LT-eligible patients with decompensated cirrhosis who would benefit (and not benef

102 ) correlates with mortality in patients with decompensated cirrhosis, who are almost invariably sarco

103 ere is a concern that the cured patient with decompensated cirrhosis will find themselves in "MELD pu

104 Incidence of decompensated cirrhosis will increase 168% to 105,430 ca

105 after their primary HCV infection developed decompensated cirrhosis within 17 months to 6 years afte

106 and the number progressing from infection to decompensated cirrhosis would decline by 65%.